WO2000016771A1 - Liquid preparations for external use containing sodium cromoglicate and method for treating or preventing eye allergic symptoms - Google Patents
Liquid preparations for external use containing sodium cromoglicate and method for treating or preventing eye allergic symptoms Download PDFInfo
- Publication number
- WO2000016771A1 WO2000016771A1 PCT/JP1999/005181 JP9905181W WO0016771A1 WO 2000016771 A1 WO2000016771 A1 WO 2000016771A1 JP 9905181 W JP9905181 W JP 9905181W WO 0016771 A1 WO0016771 A1 WO 0016771A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- external
- containing sodium
- external use
- sodium cromoglycate
- allergic symptoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
Definitions
- the present invention relates to an external solution containing sodium cromoglycate and a refreshing agent, and a method for treating or preventing allergic symptoms of the eye, characterized in that the eye is washed with an external solution containing sodium clomoglycate. Yes, used in the medical field.
- An object of the present invention is to alleviate the irritating sensation and foreign body sensation of a liquid preparation for external use containing sodium cromoglycate by adding a cooling agent, and to improve the result and compliance.
- the present invention is a liquid preparation for external use characterized by containing sodium cromoglycate and a cooling agent. Furthermore, the present invention provides a method for treating or preventing eye allergic symptoms characterized by washing eyes with an external solution containing sodium cromoglycate. There is no known method of treating or preventing such allergic symptoms of the eye.
- liquid preparation for external use of the present invention examples include eye drops, nasal drops, and eye wash.
- the amount of sodium cromoglycate used in the present invention is 0.:! In the case of eye drops or nasal drops. 33 W / V%, preferably 0.5-2 W / V%, and in the case of eyewash, 0.01-1 W / V%, preferably 0.05-0.5 W / V%.
- cooling agent used in the present invention examples include 1-menthol, dl-camphor, d-borneol, fennel oil, heart oil, heart water, and the like. can do.
- the amount of the cooling agent in the present invention is 0.0001 to 1 W / V%, preferably 0.001 to 0.1 W / V%.
- antihistamines for example, diphenhydramine hydrochloride, chlorpheniramine maleate, promethazine, diphenylpyralin hydrochloride, clemastine fumarate, etc.
- Vasoconstrictors e.g., norphenephrine hydrochloride, phenylephrine hydrochloride, naphazoline hydrochloride, gyromethazoline, mitodrine hydrochloride, methoxamine hydrochloride, detrahydrozoline nitrate, etc.
- dipotassium glycyrrhizinate allantoin
- pyridoxine hydrochloride amino Ethyl sulfonic acid
- the liquid preparation for external use of the present invention includes isotonic agents (eg, sodium chloride, etc.) and buffering agents (eg, boric acid, borax, sodium monohydrogen phosphate, sodium dihydrogen phosphate, etc.) which are usually used for liquid preparations for external use. ), Preservatives (eg, benzalkonium chloride, benzethonium chloride, butanol), thickeners (eg, carboxyvinyl polymer), stabilizers (eg, sodium edetate, glycerin, propylene glycol) Or Macrogol 4000) may be added as appropriate.
- isotonic agents eg, sodium chloride, etc.
- buffering agents eg, boric acid, borax, sodium monohydrogen phosphate, sodium dihydrogen phosphate, etc.
- Preservatives eg, benzalkonium chloride, benzethonium chloride, butanol
- thickeners eg, carboxyvinyl
- cooling agent is hardly soluble in water
- a surfactant for example, polyoxyethylene sorbitan monooleate, polyoxyethylene hydrogenated castor oil, polyoxyethylene monostearate (3 ⁇ 4F or polyoxyethylene monostearate)
- a dissolution aid such as ethylene 40 monostearate
- the liquid preparation for external use of the present invention is produced, for example, by precisely dissolving the above-mentioned cooling agent using a surfactant, and then dissolving it by appropriately adding sodium cromoglycate and the above-mentioned additives.
- the solution when sodium cromoglycate and benzalkonium chloride or the like are used in combination as a preservative, the solution may become cloudy and precipitate, but the above-mentioned surfactant (preferably, By adding ethylene monostearate at the same time, preferably in an amount of 0.01 to 0.1 WV%, it is possible to prevent the solution from disturbing and prevent the solution from becoming cloudy or sedimented.
- the above-mentioned surfactant preferably, By adding ethylene monostearate at the same time, preferably in an amount of 0.01 to 0.1 WV%, it is possible to prevent the solution from disturbing and prevent the solution from becoming cloudy or sedimented.
- the treatment or prophylaxis of eye allergic symptoms in the present invention is characterized by washing eyes with an external solution containing sodium cromoglycate, and an external solution containing sodium cromoglycate, preferably having improved compliance.
- the above topical solution containing sodium cromoglycate and a freshener is placed in a few milliliters of cap and the eyes are washed to remove pollen and dust attached to the eyes. It treats or prevents allergic symptoms of the eyes (itching of eyes, redness of eyes, etc.).
- the eye can be easily washed by washing with an external solution containing sodium cromoglycate, preferably an external solution containing sodium cromoglycate and a cooling agent. Can treat or prevent allergic symptoms.
- a predetermined amount of polyoxyethylene 40 monostearate (trade name: Nikkor MYS-40, manufactured by Nikko Chemicals Co., Ltd.) and glycerin were placed in a container, and 50 g of purified water was added thereto, followed by stirring to dissolve. Thereto, 1-menthol, d-borneol and d1-camphor were added in predetermined amounts, stirred, dissolved and made up to 100 g with purified water (first solution). In a separate container, 5 L of purified water was taken, and a predetermined amount of sodium cromoglycate, chlorpheniramine maleate, boric acid, borax, sodium edetate and 50% of sodium chloride benzalkonium solution were added and mixed. Second liquid). The first liquid was added to the second liquid and stirred, and the total amount was adjusted to 10 L with purified water to obtain an eyewash having the formulation shown in Table 1.
- Example 1 An eyewash containing no menthol, d-borneol and d1-camphor was obtained in the same manner as in Example 1 (the other components and contents were the same as in Example 1 described in Table 1).
- Example 1 Example 2
- Example 3 Kromoku, '> 1ct ⁇ u. 1 or 1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
明細書 クロモグリク酸ナトリウムを含有する外用液剤および目のァレルギ一症状の治 療または予防方法 技術分野 Description: External preparation containing sodium cromoglycate and method for treating or preventing allergic symptoms of the eye
この発明は、 クロモグリク酸ナトリウムおよび清涼化剤を含有する外用液剤、 およびク口モグリク酸ナトリゥムを含有する外用液剤で洗眼することを特徴とす る目のァレルギ一症状の治療または予防方法に関するものであり、 医療の分野で 利用される。 The present invention relates to an external solution containing sodium cromoglycate and a refreshing agent, and a method for treating or preventing allergic symptoms of the eye, characterized in that the eye is washed with an external solution containing sodium clomoglycate. Yes, used in the medical field.
背景技術 Background art
ク口モグリク酸ナトリウムを有効成分として含 する外用液剤は、了レルギ一 性疾患などの治療に点眼液や点鼻液として、 医療用や一般用に広く用いられてい る。 BACKGROUND ART External preparations containing sodium mouth molyglycate as an active ingredient are widely used for medical and general purposes as eye drops and nasal drops in the treatment of allergic diseases and the like.
また、 近年目に付着した花粉やほこりなどを洗い流して除去し、 目のアレルギ 一症状を治療または予防する目的のために、 抗アレルギー剤であるクロモグリク 酸ナトリゥムを配合した洗眼液が新たに検討されている。 Also, in recent years, eyewashes containing sodium cromoglycate, an antiallergic agent, have been newly investigated for the purpose of washing out and removing pollen and dust attached to the eyes and treating or preventing one symptom of allergic eyes. ing.
しかしながら、 こうしたクロモグリク酸ナトリウムを含有する外用液剤は、 投 与時に刺激感ゃ異物感を生じる場合があり、 患者がその使用を躊躇する、 いわゆ ¾コンプライアンスの問題があった。 However, such an external preparation containing sodium cromoglycate may cause irritation or a foreign body sensation when administered, and there is a so-called compliance problem that patients hesitate to use.
発明の開示 Disclosure of the invention
この発明は、 清涼化剤を配合することにより、 クロモグリク酸ナトリウムを含 有する外用液剤のもつ刺激感ゃ異物感を緩和し、 治 果及びコンプライアンス を向上することを目的とするものである。 An object of the present invention is to alleviate the irritating sensation and foreign body sensation of a liquid preparation for external use containing sodium cromoglycate by adding a cooling agent, and to improve the result and compliance.
すなわち、 この発明は、 クロモグリク酸ナトリウムおよび清涼化剤を含有する ことを特徴とする外用液剤である。 さらに、 この発明は、 クロモグリク酸ナトリウムを含有する外用液剤で洗眼す ることを特徴とする目のァレルギ一症状の治療または予！ ^法であり、 このよう な目のァレルギー症状の治療または予防方法は従来知られていない。 That is, the present invention is a liquid preparation for external use characterized by containing sodium cromoglycate and a cooling agent. Furthermore, the present invention provides a method for treating or preventing eye allergic symptoms characterized by washing eyes with an external solution containing sodium cromoglycate. There is no known method of treating or preventing such allergic symptoms of the eye.
発明を実施するための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
この発明の外用液剤としては、 例えば点眼液、 点鼻液、 洗眼液などが挙げられ 。 Examples of the liquid preparation for external use of the present invention include eye drops, nasal drops, and eye wash.
この発明に用いられるクロモグリク酸ナトリゥムの配合量は、 点眼液や点鼻液 の場合には、 0.：！〜 3W/V%、 好ましくは、 0.5〜2W/V%であり、 洗眼液の場合に は、 0.01〜1W/V%、 好ましくは、 0.05〜0.5W/V%である。 The amount of sodium cromoglycate used in the present invention is 0.:! In the case of eye drops or nasal drops. 33 W / V%, preferably 0.5-2 W / V%, and in the case of eyewash, 0.01-1 W / V%, preferably 0.05-0.5 W / V%.
この発明に用いられる清涼化剤としては、 例えば 1—メントール、 d l—カン フル、 d—ボルネオ一ル、 ウイキヨゥ油、 ハツ力油、 ハツ力水などが挙げられ、 これらは一種または二種以上配合することができる。 Examples of the cooling agent used in the present invention include 1-menthol, dl-camphor, d-borneol, fennel oil, heart oil, heart water, and the like. can do.
この発明における清涼化剤の配合量は、 0.0001〜； 1W/V%、 好ましくは、 0. 001~0.1W/V%である。 The amount of the cooling agent in the present invention is 0.0001 to 1 W / V%, preferably 0.001 to 0.1 W / V%.
この発明の外用液剤には、主薬成分として、クロモグリク酸ナトリゥムの他に、 例えば、 抗ヒスタミン剤 （例えば、 塩酸ジフヱンヒドラミン、 マレイン酸クロル フエ二ラミン、 プロメタジン、 塩酸ジフエ二ルピラリン、 フマル酸クレマスチン など)、血管収縮剤（例えば、塩酸ノルフエネフリン、塩酸フエ二レフリン、塩酸 ナファゾリン、 ジャイロメタゾリン、 塩酸ミ トドリン、 塩酸メ トキサミン、 硝酸 デトラハイドロゾリンなど)、 グリチルリチン酸ジカリウム、 アラントイン、塩酸 ピリ ドキシン、 アミノエチルスルホン酸などを添加してもよい。 - また、 この発明の外用液剤には、 外用液剤に通常用いられる等張化剤 （例えば 塩化ナトリゥムなど)、緩衝剤（例えばホウ酸、 ホウ砂、 リン酸一水素ナトリウム、 リン酸ニ水素ナトリゥムなど)、保存剤（例えば塩化ベンザルコニゥム、塩化ベン ゼトニゥム、 クロ口ブタノールなど)、増粘剤（例えばカルボキシビニルポリマー など)、安定化剤（例えばェデト酸ナトリウム、 グリセリン、 プロピレングリコ一 ル、 マクロゴール 4000など） を適宜添加してもよい。 さらに、 清涼化剤が水に 溶けにくい場合には、 界面活性剤 （例えばポリオキシエチレンソルビタンモノォ レエート、 ポリオキシエチレン硬化ヒマシ油、 ポリオキシエチレンモノステアレ ート （¾Fましくは、 ポリオキシエチレン 4 0モノステアレート） など） などの溶 解補助剤を用 、て溶解させることが望ましい。 In the topical solution of the present invention, in addition to sodium cromoglycate as an active ingredient, for example, antihistamines (for example, diphenhydramine hydrochloride, chlorpheniramine maleate, promethazine, diphenylpyralin hydrochloride, clemastine fumarate, etc.) ), Vasoconstrictors (e.g., norphenephrine hydrochloride, phenylephrine hydrochloride, naphazoline hydrochloride, gyromethazoline, mitodrine hydrochloride, methoxamine hydrochloride, detrahydrozoline nitrate, etc.), dipotassium glycyrrhizinate, allantoin, pyridoxine hydrochloride, amino Ethyl sulfonic acid may be added. -In addition, the liquid preparation for external use of the present invention includes isotonic agents (eg, sodium chloride, etc.) and buffering agents (eg, boric acid, borax, sodium monohydrogen phosphate, sodium dihydrogen phosphate, etc.) which are usually used for liquid preparations for external use. ), Preservatives (eg, benzalkonium chloride, benzethonium chloride, butanol), thickeners (eg, carboxyvinyl polymer), stabilizers (eg, sodium edetate, glycerin, propylene glycol) Or Macrogol 4000) may be added as appropriate. In addition, if the cooling agent is hardly soluble in water, use a surfactant (for example, polyoxyethylene sorbitan monooleate, polyoxyethylene hydrogenated castor oil, polyoxyethylene monostearate (¾F or polyoxyethylene monostearate)). It is desirable to use a dissolution aid such as ethylene 40 monostearate).
この発明の外用液剤は、 例えば上記清涼化剤を、 界面活性剤を用いて精»に 溶解させた後、 クロモグリク酸ナトリウムおよび上記添加剤を適宜加えて溶解さ せて製造する。 The liquid preparation for external use of the present invention is produced, for example, by precisely dissolving the above-mentioned cooling agent using a surfactant, and then dissolving it by appropriately adding sodium cromoglycate and the above-mentioned additives.
この発明の外用液剤において、 クロモグリク酸ナトリウムと、 保存剤として塩 化ベンザルコニゥムなどを併用した場合には、 液が白濁し沈殿を生じることがあ るが、上記の界面活性剤 （好ましくは、 ポリオキシエチレンモノステアレートな ど）を、好ましくは 0.01〜0.1W V%同時に添加す ¾ことによって、清涼化剤の溶 解効果と共に、 液の白濁や沈殿を防止することができる。 In the liquid preparation for external use of the present invention, when sodium cromoglycate and benzalkonium chloride or the like are used in combination as a preservative, the solution may become cloudy and precipitate, but the above-mentioned surfactant (preferably, By adding ethylene monostearate at the same time, preferably in an amount of 0.01 to 0.1 WV%, it is possible to prevent the solution from disturbing and prevent the solution from becoming cloudy or sedimented.
この発明における目のアレルギー症状の治療または予 法は、 クロモグリク 酸ナトリゥムを含有する外用液剤で洗眼することを特徴とするもので、 クロモグ リク酸ナトリウムを含有する外用液剤、 好ましくはコンプライアンスの向上のた め、 クロモグリク酸ナトリゥムと清涼化剤を含有する上記外用液剤を、 数 m 1ァ ィカツプに入れて目に当てて目を洗うことで、 目に付着した花粉やほこりなどを 洗い流して除去することにより、 目のアレルギー症状（目の痒み、 目の充血など） を治療または予防するものである。 The treatment or prophylaxis of eye allergic symptoms in the present invention is characterized by washing eyes with an external solution containing sodium cromoglycate, and an external solution containing sodium cromoglycate, preferably having improved compliance. The above topical solution containing sodium cromoglycate and a freshener is placed in a few milliliters of cap and the eyes are washed to remove pollen and dust attached to the eyes. It treats or prevents allergic symptoms of the eyes (itching of eyes, redness of eyes, etc.).
産業上の利用可能性 Industrial applicability
この発明の外用液剤には清涼化剤が配合されているので、 ク口モグリク酸ナト リゥムを含有する外用液剤のもつ刺激感ゃ異物感が緩和され、 治療効果及びコン プライアンスの向上に好適である。 Since a cooling agent is blended in the external preparation of the present invention, the irritation sensation and foreign body sensation of the external preparation containing sodium momoglycate are alleviated, which is suitable for improving the therapeutic effect and compliance. .
また、 クロモグリク酸ナトリウムを含有する外用液剤、 好ましくはクロモグリ ク酸ナトリゥムと清涼化剤を含有する外用液剤で洗眼することにより、 簡便に目 のァレルギ一症状を治療または予防できる。 In addition, the eye can be easily washed by washing with an external solution containing sodium cromoglycate, preferably an external solution containing sodium cromoglycate and a cooling agent. Can treat or prevent allergic symptoms.
実施例 1 Example 1
容器にポリオキシエチレン 4 0モノステアレ一ト （商品名：ニッコール MY S — 4 0、 日光ケミカルズ社製） およびグリセリンを所定量とり、 精製水 5 0 gを 加えて攪拌し溶解した。そこに、 1ーメントール、、 d—ボルネオ一ルおよび d 1 —カンフルを所定量加え、 攪拌し、 溶解して精製水で全量を 1 0 0 gとした （第 1液)。別の容器に精製水を 5 L取り、所定量のクロモグリク酸ナトリウム、マレ イン酸クロルフエ二ラミン、 ホウ酸、 ホウ砂、 ェデト酸ナトリウムおよび塩ィ匕べ ンザルコニゥム液 5 0 %を加えて混和した （第 2液)。 第 2液に第 1液を加えて 攪拌し、 精製水で全量を 1 0 Lとして、 表 1に記載の処方の洗眼液を得た。 実施例 2 A predetermined amount of polyoxyethylene 40 monostearate (trade name: Nikkor MYS-40, manufactured by Nikko Chemicals Co., Ltd.) and glycerin were placed in a container, and 50 g of purified water was added thereto, followed by stirring to dissolve. Thereto, 1-menthol, d-borneol and d1-camphor were added in predetermined amounts, stirred, dissolved and made up to 100 g with purified water (first solution). In a separate container, 5 L of purified water was taken, and a predetermined amount of sodium cromoglycate, chlorpheniramine maleate, boric acid, borax, sodium edetate and 50% of sodium chloride benzalkonium solution were added and mixed. Second liquid). The first liquid was added to the second liquid and stirred, and the total amount was adjusted to 10 L with purified water to obtain an eyewash having the formulation shown in Table 1. Example 2
実施例 1と同様にして、 表 1に記載の処方の点鼻液を得た。 In the same manner as in Example 1, nasal drops having the formulations shown in Table 1 were obtained.
実施例 3 Example 3
実施例 1と同様にして、 表 1に記載の処方の点眼液を得た。 In the same manner as in Example 1, eye drops having the formulations shown in Table 1 were obtained.
実施例 4 Example 4
実施例 1と同様にして、 1一メントール、 d—ボルネオールおよび d 1—カン フルを含有しない洗眼液を得た（他の成分 ·含量については、表 1に記載の実施例 1と同じ)。 An eyewash containing no menthol, d-borneol and d1-camphor was obtained in the same manner as in Example 1 (the other components and contents were the same as in Example 1 described in Table 1).
成分名 実施例 1 実施例 2 実施例 3 クロモク、' >1ク ト π u . 1 or 1 Ingredient name Example 1 Example 2 Example 3 Kromoku, '> 1ct π u. 1 or 1
1 リウム 丄 g ρ 1 Lum 丄 g ρ
& 6 レイ 1 ン✓赖ク口ルフヱ二ラノ ミ、ン 0 U U 丄 <J 0 η Π & 6 Ray 1 Ink-open lanyard, 0 U U 丄 <J 0 η Π
VJ 1丄 * RJ 塩SU酷Pi 十フマ 11ン π Π ς VJ 1 丄 * RJ Shi SU SU Pi Pi 10 Fuma 11 π Π ς
y r ノ r ソ ノ " 0 nリ 1丄 π υ， υ丄 リ , π 1 o y r no r sono "0 n 1 1 π υ, υ 丄, π 1 o
•*m1 Liノ 1 ノ ノ o β • * m1 Li no 1 no o β
1 1
ノ ソ ソ 丄 ソ
*ノ" ° nレし0しレ、ノノン 7、、 1リ ϊ —7―一ノ Jしレ 0. 5 ホウ酸 0. 8 * Bruno "° n Les and 0 may, Nonon 7 ,, 1 Li ϊ -7- one Roh J may 0.5 boric acid 0.8
ホヮ砂 0. 03 Ho sand 0.03
一ッ J一ノレ M Y o— 4 U 0. 02 0. 01 0. 02 塩化ベンザルコニゥム液 50% 0. 02 0. 02 0. 02One J One hole M Y o— 4 U 0.02 0.01 0.02 Benzalkonium chloride 50% 0.02 0.02 0.02
1—メントール 0. 004 0. 002 0. 004 d—ボルネオ一ル 0. 002 0. 001 0. 002 d 1—カンフル 0. 002 0. 001 0. 002 ハツ力油 0. 01 精製水 適直 適量 適量 合計 100m l 100ml 100m l 1—Menthol 0.004 0.002 0.004 d—Borneoyl 0.002 0.001 0.002 d 1—Camphor 0.002 0.001 0.002 Heart oil 0.01 Purified water Suitable amount Total 100ml 100ml 100ml
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27014698 | 1998-09-24 | ||
| JP10/270146 | 1998-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2000016771A1 true WO2000016771A1 (en) | 2000-03-30 |
Family
ID=17482192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1999/005181 Ceased WO2000016771A1 (en) | 1998-09-24 | 1999-09-22 | Liquid preparations for external use containing sodium cromoglicate and method for treating or preventing eye allergic symptoms |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2000016771A1 (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001158750A (en) * | 1999-12-02 | 2001-06-12 | Lion Corp | Method for improving sustainability of ophthalmic composition and anti-allergic medicine |
| JP2002053465A (en) * | 2000-08-11 | 2002-02-19 | Taisho Pharm Ind Ltd | Anti-allergy topical solution |
| JP2002097129A (en) * | 2000-07-21 | 2002-04-02 | Rohto Pharmaceut Co Ltd | Eye lotion |
| JP2002114686A (en) * | 2000-10-11 | 2002-04-16 | Hisamitsu Pharmaceut Co Inc | Eye drop composition |
| JP2004149526A (en) * | 2002-10-11 | 2004-05-27 | Rohto Pharmaceut Co Ltd | Aqueous liquid composition |
| JP2004339213A (en) * | 2003-04-25 | 2004-12-02 | Rohto Pharmaceut Co Ltd | Nasal drops |
| JP2005015499A (en) * | 2000-07-21 | 2005-01-20 | Rohto Pharmaceut Co Ltd | Eye lotion |
| JP2005239683A (en) * | 2004-02-27 | 2005-09-08 | Taisho Pharmaceut Co Ltd | Ophthalmic agent |
| JP2005239681A (en) * | 2004-02-27 | 2005-09-08 | Taisho Pharmaceut Co Ltd | Ophthalmic agent |
| JP2005247875A (en) * | 2000-07-21 | 2005-09-15 | Rohto Pharmaceut Co Ltd | Ophthalmic preparation |
| JP2006321790A (en) * | 2005-04-18 | 2006-11-30 | Taisho Pharmaceut Co Ltd | Ophthalmic agent |
| JP2008143845A (en) * | 2006-12-11 | 2008-06-26 | Hoshienu Seiyaku Kk | Nasal drop composition and nasal drop spraying tool |
| JP2008189677A (en) * | 2008-03-10 | 2008-08-21 | Rohto Pharmaceut Co Ltd | Washing agent |
| JP2010254722A (en) * | 2000-07-21 | 2010-11-11 | Rohto Pharmaceut Co Ltd | Eye lotion |
| JP2010280722A (en) * | 2003-04-25 | 2010-12-16 | Rohto Pharmaceut Co Ltd | Nasal drops |
| JP2013018797A (en) * | 2012-10-31 | 2013-01-31 | Taisho Pharmaceutical Co Ltd | Ophthalmic agent |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0670161A1 (en) * | 1992-05-26 | 1995-09-06 | The Procter & Gamble Company | Pharmaceutical compositions containing sodium cromoglycate and a bicyclic aromatic flavour |
| JPH09132526A (en) * | 1995-11-09 | 1997-05-20 | Lion Corp | Eye drops |
| JPH101442A (en) * | 1996-06-12 | 1998-01-06 | Taisho Pharmaceut Co Ltd | Rhinitis nasal drops |
| WO1998013040A1 (en) * | 1996-09-26 | 1998-04-02 | Rohto Pharmaceutical Co., Ltd. | Eyedrops |
-
1999
- 1999-09-22 WO PCT/JP1999/005181 patent/WO2000016771A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0670161A1 (en) * | 1992-05-26 | 1995-09-06 | The Procter & Gamble Company | Pharmaceutical compositions containing sodium cromoglycate and a bicyclic aromatic flavour |
| JPH09132526A (en) * | 1995-11-09 | 1997-05-20 | Lion Corp | Eye drops |
| JPH101442A (en) * | 1996-06-12 | 1998-01-06 | Taisho Pharmaceut Co Ltd | Rhinitis nasal drops |
| WO1998013040A1 (en) * | 1996-09-26 | 1998-04-02 | Rohto Pharmaceutical Co., Ltd. | Eyedrops |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001158750A (en) * | 1999-12-02 | 2001-06-12 | Lion Corp | Method for improving sustainability of ophthalmic composition and anti-allergic medicine |
| JP2016147889A (en) * | 2000-07-21 | 2016-08-18 | ロート製薬株式会社 | Eye drops |
| JP2002097129A (en) * | 2000-07-21 | 2002-04-02 | Rohto Pharmaceut Co Ltd | Eye lotion |
| JP2014062133A (en) * | 2000-07-21 | 2014-04-10 | Rohto Pharmaceut Co Ltd | Eye drop |
| JP2013100366A (en) * | 2000-07-21 | 2013-05-23 | Rohto Pharmaceutical Co Ltd | Eye lotion |
| JP2005015499A (en) * | 2000-07-21 | 2005-01-20 | Rohto Pharmaceut Co Ltd | Eye lotion |
| JP2015078242A (en) * | 2000-07-21 | 2015-04-23 | ロート製薬株式会社 | Eye drop |
| JP2010254722A (en) * | 2000-07-21 | 2010-11-11 | Rohto Pharmaceut Co Ltd | Eye lotion |
| JP2005247875A (en) * | 2000-07-21 | 2005-09-15 | Rohto Pharmaceut Co Ltd | Ophthalmic preparation |
| JP2018009014A (en) * | 2000-07-21 | 2018-01-18 | ロート製薬株式会社 | Eye drops |
| JP2002053465A (en) * | 2000-08-11 | 2002-02-19 | Taisho Pharm Ind Ltd | Anti-allergy topical solution |
| JP2002114686A (en) * | 2000-10-11 | 2002-04-16 | Hisamitsu Pharmaceut Co Inc | Eye drop composition |
| JP2004149526A (en) * | 2002-10-11 | 2004-05-27 | Rohto Pharmaceut Co Ltd | Aqueous liquid composition |
| JP2010280722A (en) * | 2003-04-25 | 2010-12-16 | Rohto Pharmaceut Co Ltd | Nasal drops |
| JP2004339213A (en) * | 2003-04-25 | 2004-12-02 | Rohto Pharmaceut Co Ltd | Nasal drops |
| JP2005239681A (en) * | 2004-02-27 | 2005-09-08 | Taisho Pharmaceut Co Ltd | Ophthalmic agent |
| JP2005239683A (en) * | 2004-02-27 | 2005-09-08 | Taisho Pharmaceut Co Ltd | Ophthalmic agent |
| JP2006321790A (en) * | 2005-04-18 | 2006-11-30 | Taisho Pharmaceut Co Ltd | Ophthalmic agent |
| JP2008143845A (en) * | 2006-12-11 | 2008-06-26 | Hoshienu Seiyaku Kk | Nasal drop composition and nasal drop spraying tool |
| JP2008189677A (en) * | 2008-03-10 | 2008-08-21 | Rohto Pharmaceut Co Ltd | Washing agent |
| JP2013018797A (en) * | 2012-10-31 | 2013-01-31 | Taisho Pharmaceutical Co Ltd | Ophthalmic agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1050514C (en) | Antiallergic composition for ophthalmic or nasal use | |
| WO2000016771A1 (en) | Liquid preparations for external use containing sodium cromoglicate and method for treating or preventing eye allergic symptoms | |
| JP2001187728A (en) | Ophthalmic composition | |
| JP2017019846A (en) | Eye drop | |
| JP2011093923A (en) | Ophthalmic solution | |
| JP5653466B2 (en) | Flunisolide-containing composition for mucosa | |
| KR20010012521A (en) | Antiseptic composition | |
| JP2014185161A (en) | Agent for treating fatty liver with carbostyril derivative including cilostazol | |
| JP5132015B2 (en) | Eye drop composition | |
| JP3502574B2 (en) | Eye ointment for treatment of eye infections | |
| JP3876232B2 (en) | Ophthalmic preparations, eye drops, artificial tears, contact lens care products, eye washes, and eye ointments | |
| JP4904687B2 (en) | Ophthalmic composition | |
| JP2003073303A (en) | Method for maintaining refreshing activity of eye drops | |
| JP4801300B2 (en) | Liquid composition for external use | |
| JP4442118B2 (en) | Stable eye drops | |
| JP2004059583A (en) | Eyewashing liquid and nasal drop containing sodium cromoglycate | |
| JP2002241278A (en) | Eyewash and nasal drop containing sodium cromoglycate | |
| JP5172678B2 (en) | Stabilized and preserved ketotifen-containing ophthalmic composition | |
| JP2005247802A (en) | Eye drops | |
| JPH04327533A (en) | Anti-allergic agent for locally administering to mucosa | |
| JP2009084235A (en) | Ophthalmic anti-hyperemia agent and anti-hyperemia ophthalmic composition | |
| JP4524538B2 (en) | Ophthalmic composition | |
| JPWO2000016771A1 (en) | Topical solution containing sodium cromoglycate and method for treating or preventing eye allergy symptoms | |
| JP4695315B2 (en) | Eye drops | |
| JP2004143155A (en) | Ophthalmic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase |